Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trialJohann S. de Bono, Ulrik Lassen, Srinivas Ghatta et al.|The Lancet Oncology|2019Cited by 228
First‐in‐human study with intratumoral administration of a CD40 agonistic antibody, ADC‐1013, in advanced solid malignanciesSandra Irenaeus, Gustav Ullenhag, Dorte Nielsen et al.|International Journal of Cancer|2019Cited by 142
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer, Nagy Habib, Mikael H. Sodergren et al.|Cell Reports Medicine|2025Cited by 12
850 Interim results for phase 1b dose expansion of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumour malignanciesRuth Plummer, Nagy Habib, Mikael H. Sodergren et al.|Regular and Young Investigator Award Abstracts|2022Cited by 1
Abstract LB192: MTL-CEBPA in combination with pembrolizumab converts an immune desert to an inflamed TME in solid tumors resistant to checkpoint blockadeRuth Plummer, Nagy Habib, Mikael H. Sodergren et al.|Cancer Research|2023Cited by 1